Research use only · common protocol
Humanin 10 mg vial dosage
A 10 mg Humanin vial mixed with 1 mL of bacteriostatic water gives 10 mg/mL, so 3 mg is 30 units (0.3 mL) on a U-100 insulin syringe. At 3 mg a dose, one vial holds 3 doses.
Email me this plan, with a reminder before the vial's 28-day mark →
The common Humanin protocol is 0.5-5 mg, commonly once daily; some protocols use 2 to 3 times a week instead - common practice, not a dose established in trials. Evidence, side effects and legal status are on the full Humanin dosing page.
Humanin 10 mg vial at a glance
- Vial
- 10 mg of Humanin per vial
- Common dose
- 0.5-5 mg
- How often
- commonly once daily; some protocols use 2 to 3 times a week instead
- Mixing example
- 1 mL bacteriostatic water = 10 mg/mL; 1 unit = 100 mcg
- Doses per vial
- 20 at 500 mcg · 3 at 3 mg · 2 at 5 mg
- Cycle
- 4-12 weeks, then 4-8 weeks off
What Humanin is
- Class:
- Mitochondrial-derived peptide (24 amino acids)
- Also called:
- HN
- Used for:
- Sold online for anti-aging and neuroprotection claims. Studied almost entirely in cell cultures and rodents; no completed human efficacy trial was located for this page.
- Human evidence:
- Animal / lab only. No completed human clinical trial administering humanin to people was located for this page. The published literature is overwhelmingly cell-culture and rodent work on neuroprotection, metabolic signalling and cardiovascular stress. Human research that exists measures circulating humanin levels in blood as an observational marker, not the effect of dosing someone with it, so human efficacy is not established.
- US status:
- Research use only. Not FDA-approved for any indication in the US. No verified source establishing FDA, TGA or EMA approval was found for this page. Sold online as a research chemical and not legally marketed for human use.
The full picture, with every study: Humanin guide.
Units per dose: Humanin 10 mg vial
| Water added | Concentration | 1 unit = | 500 mcg | 3 mg | 5 mg |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 100 mcg | 5 units | 30 units | 50 units |
| 2 mL | 5 mg/mL | 50 mcg | 10 units | 60 units | 100 units |
| 3 mL | 3.33 mg/mL | 33.33 mcg | 15 units | 90 units | over 100 units |
U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. Water volumes are examples. Other numbers: dosage calculator.
Every dose from 500 mcg to 5 mg, in units
With 1 mL of water in a 10 mg vial (10 mg/mL). Every dose across the common range, so you can read off any dose. The sources give a range, not a week-by-week schedule.
| Dose | Draw on a U-100 syringe | Volume | Doses per vial |
|---|---|---|---|
| 500 mcg | 5 units | 0.05 mL | 20 |
| 1 mg | 10 units | 0.1 mL | 10 |
| 2 mg | 20 units | 0.2 mL | 5 |
| 3 mg | 30 units | 0.3 mL | 3 |
| 4 mg | 40 units | 0.4 mL | 2 |
| 5 mg | 50 units | 0.5 mL | 2 |
How many doses a 10 mg vial holds
| Dose | Doses per vial | Weeks per vial |
|---|---|---|
| 500 mcg | 20 | 2.9-10 |
| 3 mg | 3 | 0.4-1.5 |
| 5 mg | 2 | 0.3-1 |
Weeks per vial at the common frequency (commonly once daily; some protocols use 2 to 3 times a week instead). Doses per vial do not depend on how much water you add.
Email me my Humanin 10 mg vial plan
Pick your water volume and dose and I will email you the numbers for this vial - units, volume, doses per vial and how long it lasts - plus the mixing and storage steps, and a reminder before the mixed vial reaches 28 days.
The common Humanin protocol
| Dose | 0.5-5 mg per injection |
|---|---|
| How often | commonly once daily; some protocols use 2 to 3 times a week instead |
| Timing | Often taken in the morning |
| Route | Subcutaneous injection |
| Cycle | 4-12 weeks |
| Break | 4-8 weeks |
| Often paired with | MOTS-c |
| Sources agree? | Partly - the sources differ, and the ranges above cover them |
Common practice from the vendors and clinics that publish it, not a dose tested in trials. Where it comes from: [1], [2], [3]. I do not give week-by-week titration: none of these sources states one.
Supplies for one cycle with 10 mg vials
Counted for the low and high ends of the common protocol, mixing each vial with 1 mL of water. One new syringe per injection.
| Plan | Injections | 10 mg vials | Insulin syringes | Bacteriostatic water | Alcohol swabs |
|---|---|---|---|---|---|
| 500 mcg, 2×/week, 4 weeks | 8 | 1 | 8 | 1 mL (1 × 10 mL bottle) | 18 (1 × 100-pack) |
| 5 mg, 7×/week, 12 weeks | 84 | 42 | 84 | 42 mL (5 × 10 mL bottles) | 252 (3 × 100-pack) |
Arithmetic on the protocol and this vial size. Swabs: two per vial mixed (both stoppers) and two per injection (vial stopper and skin). An opened multi-dose vial has a use-by date (see storage), which on a slow schedule can matter more than the dose count. Plan your own numbers with the protocol builder.
How to mix a 10 mg Humanin vial
For this vial: 1 mL of bacteriostatic water makes 10 mg/mL, so 3 mg is 30 units (0.3 mL) on a U-100 insulin syringe. Pick a different volume from the units table if you want bigger or smaller draws; the number of doses stays the same.
- Wipe the rubber stoppers of both the peptide vial and the bacteriostatic water vial with an alcohol swab and let the alcohol dry. [4][5]
- With a new sterile needle and syringe, draw up the amount of bacteriostatic water you have chosen for the dilution. [4][5][6]
- Inject the water into the peptide vial by aiming the stream against the inside glass wall, which helps prevent foaming. [7]
- Swirl or roll the vial gently until the powder has fully dissolved; do not shake it. Do not inject the solution if it is cloudy or has particles in it. [4][5][7]
- Label the vial with the date and time it was mixed, the amount of water added and how long it can be used after mixing. [4]
- Store the mixed vial in the refrigerator at 2-8°C (36-46°F) and do not freeze it. [7]
Step by step with pictures: how to reconstitute peptides. About the water itself: bacteriostatic water.
Storing Humanin vials
- Freeze-dried (lyophilized) peptide keeps far longer than peptide in solution; peptide suppliers advise storing the powder at -20°C away from bright light. [8]
- Protect peptide vials from heat and light. [8][9]
- Avoid repeated freeze-thaw cycles; a prescription peptide label also says not to freeze a vial once it has been mixed. [7][8]
- Once a multi-dose vial, such as bacteriostatic water, has been opened (needle-punctured), date it and discard it within 28 days unless its manufacturer states another date. [10][11]
More detail: peptide storage and shelf life.
Injecting safely
- Clean the injection site with an alcohol swab and let the skin dry completely before injecting. [12][13]
- Pinch up a fold of skin and fat (not muscle) and insert the needle at a 45- to 90-degree angle: 90 degrees where there is enough fatty tissue, 45 degrees where there is little. [12][13][14]
- Pulling back on the plunger (aspiration) is not necessary for a subcutaneous injection, because the chance of the needle being in a blood vessel is small. [12]
- Inject slowly, at roughly 10 seconds per mL. [12]
- Common sites are the belly, the thigh and the upper arm; rotate sites, keeping each injection at least 1 inch (2.5 cm) from the last. [7][12][13]
Hygiene and warning signs
- Use a new sterile needle and syringe for every injection and every time you enter a vial; never reuse them. [6][10][13]
- Never share needles, syringes or pens with anyone, even if the needle is changed; unsafe injection practices spread hepatitis B, hepatitis C and HIV. [6][9][10]
- Put used needles and syringes in a sharps disposal container straight away (FDA-cleared if possible), never loose in the trash, recycling or toilet, and dispose of the container following your community's guidelines. [15][16]
- Contact a health care provider if the injection site shows signs of infection, such as redness, swelling, red streaks or a fever. [13]
Where to inject: subcutaneous injection sites.
How Humanin works
- Humanin is a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene (MT-RNR2) of the mitochondrial genome rather than by a nuclear gene, which makes it a mitochondrial-derived peptide. [17][18]
- It was found in 2001 by screening for something that would stop neuronal cells dying, and the gene identified encoded a short polypeptide that was secreted into the culture medium and prevented cell death caused by several familial Alzheimer's disease genes and by amyloid-beta. The rescue depended on the peptide's exact sequence. [19]
- Cell work places its receptor in the cytokine family: protection of neurons required gp130, knocking down ciliary neurotrophic factor receptor alpha or the IL-27 receptor subunit WSX-1 reduced humanin binding and removed its protective effect, and in reconstituted assays the peptide drew the three subunits together. Separately, humanin binds insulin-like growth factor binding protein 3 with high affinity at its heparin-binding domain, without competing with IGF-I for it. [20][21]
What the Humanin research found
Human evidence: animal / lab only. Each result says what was studied.
- Lab studyIn the original cell experiments, humanin abolished the death of neuronal cells caused by a wide range of familial Alzheimer's disease genes and by amyloid-beta, but did not protect against death caused by two unrelated insults, so the effect was specific rather than general. [19]
- Animal studyInfusing humanin into the brain ventricles of rats improved whole-body insulin sensitivity, an effect that depended on STAT-3 signalling in the hypothalamus and disappeared when that signalling was blocked. Intravenous humanin analogues reproduced it, a potent analogue lowered blood glucose in Zucker diabetic fatty rats, and the same paper reports that detectable humanin falls with age in rodent tissue and in the circulation of mice and people. [22]
- Animal studyOverexpressing humanin extended lifespan in C. elegans, dependent on the daf-16/FOXO gene. Treating middle-aged mice twice weekly with the analogue HNG improved metabolic measures and lowered inflammatory markers, and circulating humanin was reported to be higher in the children of centenarians than in age-matched controls and lower in people with Alzheimer's disease or MELAS. [23]
- Animal studyHumanin given to aged mice improved cognition, and in human cohorts a variant in the humanin-coding region of the mitochondrial genome (rs2854128) was associated with lower circulating humanin and with faster cognitive ageing. The mice were dosed; the people were only measured. [24]
- Animal studyThe longest animal experiment located gave the humanin analogue HNG to female mice by intraperitoneal injection twice weekly from 18 to 32 months of age. Treated hearts had less collagen deposition, fewer proliferating fibroblasts, lower TGF-beta1, FGF-2 and MMP-2, and less myocardial apoptosis than untreated old mice. [25]
- Human studyThe human research measures the peptide, not the effect of taking it. High-intensity interval exercise raised humanin in the plasma and vastus lateralis muscle of 10 healthy untrained men, and in a separate randomised comparison acute endurance exercise significantly raised circulating humanin while resistance exercise did not. [17][26]
Humanin side effects and risks
No completed human trial has given humanin to anyone, so no human side-effect data exists. Everything below comes from animal and cell work, much of it using a modified analogue rather than the native peptide.
- Animal studyThe cardiac and metabolomic mouse studies dosed the analogue HNG, also written S14G-humanin, rather than native humanin, and were designed around efficacy endpoints such as collagen deposition or plasma metabolites. Neither reports a systematic adverse-event or toxicology assessment, so they cannot stand in for one. [25][27]
- Lab studyWhat is known about its reach argues for caution rather than comfort. Humanin binds IGFBP-3 with high affinity and acts through a receptor complex shared with cytokine signalling, and in cells the interaction with IGFBP-3 was both synergistic and antagonistic depending on the cell type - blocking IGFBP-3-induced apoptosis in one line while leaving the response intact in others. [20][21]
Other things to know
- No completed human trial of administered humanin was located, so no human safety profile is established.
- No human pharmacokinetic study was located, so no human half-life is established and no dosing interval has any evidence-based basis.
- Sold as a "research chemical," which is not manufactured, tested or labelled to any pharmaceutical standard for human use.
Reported side effects and what the studies measured: Humanin side effects.
Where this vial size comes from
Humanin is sold as a 10 mg vial by the pages below, each checked on the date shown. I list them as evidence that this size exists, not as a recommendation to buy from them.
- Next Level PharmvendorLists it as: Size selector: "Choose an option 10mg" · checked 2026-09-28
- BioEdge Research LabsvendorLists it as: "Vial Size: 3 mL sterile vial"; "Fill: 10mg" · checked 2026-09-28
The doses come from the sourced common protocol on the Humanin dosing page, and every number on this page is arithmetic on those doses and this vial size.
Other Humanin vial sizes
- 5 mg vial
- 10 mg
Where to buy Humanin for research
Sold for research use only. Listed by Next Level Pharm and BioEdge Research Labs; compare them on my vendors page or see the listing on the Humanin page.
Questions
- How much water do I add to a 10 mg Humanin vial?
- There is no single correct amount: water changes how many units a dose is, not how many doses the vial holds. With 1 mL the vial is 10 mg/mL and 3 mg is 30 units (0.3 mL) on a U-100 insulin syringe. The units table gives 1, 2, 3 mL.
- How many doses are in a 10 mg Humanin vial?
- 20 doses at 500 mcg, 3 doses at 3 mg, 2 doses at 5 mg.
- How long does a 10 mg Humanin vial last?
- At 3 mg a dose and commonly once daily, about 0.4-1.5 weeks. How long a mixed vial keeps is a separate limit; see storage below.
- How many 10 mg vials do I need for a cycle?
- 1 vial at 500 mcg 2 times a week for 4 weeks; 42 vials at 5 mg 7 times a week for 12 weeks.
- What does 1 unit equal in a 10 mg Humanin vial?
- 100 mcg with 1 mL, 50 mcg with 2 mL, 33.33 mcg with 3 mL of bacteriostatic water, on a U-100 syringe.
References (27 sources)
- [1] Peptide Dosing Protocols: SC, milligram-range per session, daily to 2-3x/week, 4-12 week cycles with an equal off period, 20 mg vial example (other, checked 2026-09-27)
- [2] The Peptide Catalog: 0.5-2 mg/day SC, most at 1 mg daily, AM, 8-12 weeks on/4-8 off, 5 mg vial, stacked with MOTS-c (other, checked 2026-09-27)
- [3] PeptideWiki: Native humanin 1-5 mg SC once daily, 8-12 weeks on/4 off, 5 mg vial, paired with MOTS-c; distinct from the far lower-dose HNG analog (other, checked 2026-09-27)
- [4] OpenStax, Rice University: 12.3 Preparing Unit-Dose Packaged Medications - Clinical Nursing Skills
- [5] East Carolina University College of Nursing: Reconstitution of Medication
- [6] Centers for Disease Control and Prevention: Considerations for Blood Glucose Monitoring and Insulin Administration
- [7] DailyMed, National Library of Medicine: SEROSTIM (somatropin) for injection - prescribing information and instructions for use
- [8] GenScript: Peptide Storage and Handling Guidelines
- [9] DailyMed, National Library of Medicine: OZEMPIC (semaglutide) injection - prescribing information
- [10] Centers for Disease Control and Prevention: Preventing Unsafe Injection Practices
- [11] Pfizer: Bacteriostatic Water for Injection, USP - prescribing information
- [12] OpenStax, Rice University: 12.5 Administering Subcutaneous Injections - Clinical Nursing Skills
- [13] MedlinePlus, National Library of Medicine: Subcutaneous (SQ) injections
- [14] Centers for Disease Control and Prevention: Chapter 6: Vaccine Administration - Pink Book
- [15] US Food and Drug Administration: Best Way to Get Rid of Used Needles and Other Sharps
- [16] US Food and Drug Administration: DOs and DON'Ts of Proper Sharps Disposal
- [17] Woodhead JST, D'Souza RF, Hedges CP et al. High-intensity interval exercise increases humanin, a mitochondrial encoded peptide, in the plasma and muscle of men. J Appl Physiol (1985). 2020;128(5):1346-1354.
- [18] Miller B, Wan J. Assay Development and Measurement of the Aging Biomarker Humanin. Methods Mol Biol. 2020;2144:201-209.
- [19] Hashimoto Y, Niikura T, Tajima H et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98(11):6336-41.
- [20] Hashimoto Y, Kurita M, Aiso S et al. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Mol Biol Cell. 2009;20(12):2864-73.
- [21] Ikonen M, Liu B, Hashimoto Y et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci U S A. 2003;100(22):13042-7.
- [22] Muzumdar RH, Huffman DM, Atzmon G et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334.
- [23] Yen K, Mehta HH, Kim SJ et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(12):11185-11199.
- [24] Yen K, Wan J, Mehta HH et al. Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans. Sci Rep. 2018;8(1):14212.
- [25] Qin Q, Mehta H, Yen K et al. Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol. 2018;315(5):H1127-H1136.
- [26] von Walden F, Fernandez-Gonzalo R, Norrbom J et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- [27] Mehta HH, Xiao J, Ramirez R et al. Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment. Metabolomics. 2019;15(6):88.